Dr. Andrew Poklepovic, MD

Dr. Poklepovic practices at VCU Medical Center in Richmond, Virginia, part of Commonwealth of Virginia.

Dr. Poklepovic's NPI, 1356550800, was assigned on May 22, 2007. Dr. Poklepovic graduated from University of South Florida College of Medicine in 2004. Dr. Poklepovic holds Virginia license 0101241787.

Dr. Poklepovic's primary practice is VCU Medical Center, at 1250 East Marshall Street, Richmond, VA 23298 in Richmond City. The practice phone is (804) 828-9000.

Dr. Poklepovic's primary practice is VCU Medical Center in Richmond, Virginia, part of Commonwealth of Virginia. Dr. Poklepovic is also affiliated with VCU Health Tappahannock Hospital. The medical group on file is MCV Physicians. Dmand AI also links Dr. Poklepovic to 1 more hospital and 1 urgent care center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Poklepovic practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Poklepovic's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Poklepovic is licensed in Virginia.

CMS data shows 592 Medicare services from Dr. Poklepovic across 6 procedure codes in 2024, for 194 Medicare patients. Medicare paid $43,635 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 194 Medicare patients who saw Dr. Poklepovic in 2024. The largest group is 65 to 74, with 91 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 2.20, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Poklepovic's median patient age at 73, with 43% women.

In 2024, Dr. Poklepovic wrote 220 Medicare Part D claims for 75 patients. 74% of them were for generic drugs. CMS names the drug for 120 of them, across 8 drugs with 11 or more claims each, at $433,112 in total drug cost. In 2023, CMS named 27 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Poklepovic for performance year 2024, reported as part of a group. Dr. Poklepovic accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 106 papers to Dr. Poklepovic, published from 2012 to 2025. 2018 was the busiest year, with 12. The most frequent topics are Cell Line, Tumor, Drug Synergism and Antineoplastic Combined Chemotherapy Protocols. Dr. Poklepovic has published most often in Cancer Biol Ther. Dr. Poklepovic's most frequent co-authors are Jason J. Luke, MD, Timothy Stanwood Webb, MD and Antonio Abbate, MD.

Dmand AI links Dr. Poklepovic to 10 clinical trials, 5 of them phase 2 studies. 10 are still active or recruiting. Conditions studied include Melanoma, Nevi and Melanomas and Carcinoma, Merkel Cell. National Cancer Institute (NCI) sponsors the most, 8.

CMS Open Payments shows 108 general payments to Dr. Poklepovic from 13 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 63% of the total. Bristol-Myers Squibb Company paid the most, $89,005.

Dr. Poklepovic graduated from University of South Florida College of Medicine in 2004.